Rimonabant research shows mixed picture

By: Pulse

Rimonabant has some benefits at reducing risk factors for heart disease in obese patients, but the overall picture is mixed, international research concludes.

A randomised controlled trial comparing rimonabant with placebo in 839 patients found no significant reduction for percentage atheroma volume, but did find the drug significantly reduced total atheroma volume, over 18 months.
Click here to find out more!

The research also found an increase in HDL cholesterol levels of 22.4% for patients on rimonabant compared with 6.9% for controls, but LDL cholesterol levels and blood pressure changes did not differ significantly between treatment groups.

View original article